Comparative Response Patterns to Immune Checkpoint Inhibition in Merkel Cell Carcinoma: A Merkel Cell Polyomavirus-Stratified Systematic Review

Abstract

Keywords

Merkel cell carcinoma checkpoint inhibitors PD-1 PD-L1 Merkel cell polyomavirus precision oncology

Get full access to this article

View all access options for this article.

References

Harms

Moore

, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol. 2018;15(12):763-776. doi:10.1038/s41571-018-0103-2

Nghiem

Bhatia

Lipson

, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542-2552. doi:10.1056/NEJMoa1603702

Kaufman

Russell

Hamid

, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma. Lancet Oncol. 2016;17(10):1374-1385. doi:10.1016/S1470-2045(16)30364-3

D’Angelo

Lebbe

Mortier

, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma. J Immunother Cancer. 2021;9(7):e002646. doi:10.1136/jitc-2021-002646

Knepper

Montesion

Russell

, et al. The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019;25(19):5961-5971. doi:10.1158/1078-0432.CCR-18-4159